The global Metastatic Melanoma Therapeutics Market driven by increasing cancer awareness and funding
![]() |
Metastatic Melanoma Therapeutics Market |
Metastatic
melanoma is the deadliest and most aggressive form of skin cancer. It arises
due to the uncontrolled growth and spread of pigment-producing cells known as
melanocytes. Melanoma can spread from the primary site to other organs, most
commonly the lungs, brain, liver, or bones. Currently, there are a number of treatment
options available to treat metastatic melanoma including chemotherapy, targeted
therapy, immunotherapy, and radiation therapy. The key advantage of these
therapies is that they help improve survival rates and quality of life of
patients. With increasing awareness about skin cancer and rising healthcare
expenditure, the demand for metastatic melanoma therapeutics is expected to
grow substantially in the coming years.
The
global Metastatic Melanoma Therapeutics Market is estimated to be valued at US$
9228.85 Mn in 2024 and is expected to exhibit a CAGR of 4.9% over the forecast
period 2024-2031, as highlighted in a new report published by Coherent Market
Insights.
Market key trends: One of the major trends witnessed in the metastatic melanoma
therapeutics market is significant increase in research and development
activities. There are continuous efforts by market players and research
institutes to develop novel drugs and treatment approaches with improved
efficacy and reduced side effects. For instance, recently, several immune
checkpoint inhibitors have been approved or are in pipeline that may offer
improved outcomes. Coupled with this, combination therapies using drugs that
target different pathways are being explored extensively to enhance treatment
response rates. This is anticipated to boost the market growth during the
forecast period.
Porter's Analysis
Threat of new entrants: The threat of new entrants in the metastatic melanoma
therapeutics market is moderate as the market is highly consolidated and
requires extensive R&D and clinical trials for drug development.
Bargaining power of buyers: The bargaining power of buyers is moderate owing to
the presence of critical and life-saving drugs for metastatic melanoma
treatment limiting options for patients.
Bargaining power of suppliers: The bargaining power of suppliers is low due to
the presence of a large number of raw material suppliers required for drug
manufacturing.
Threat of new substitutes: The threat of new substitutes is moderate as invasive
surgeries and radiation therapy are alternative options for unresectable
metastatic melanoma treatment.
Competitive rivalry: The competitive rivalry in the market is high due to the
presence of major players focusing on drug innovation, strategic collaborations,
and new product launches.
Key Takeaways
The Global
Metastatic Melanoma Therapeutics Market Demand is expected to witness
high growth over the forecast period. The global Metastatic Melanoma
Therapeutics Market is estimated to be valued at US$ 9228.85 Mn in 2024 and is
expected to exhibit a CAGR of 4.9% over the forecast period 2024-2031.
Regional analysis
North America is expected to hold the largest share of the global metastatic
melanoma therapeutics market during the forecast period. Factors such as the
high prevalence of skin cancer, increasing healthcare expenditure, the
availability of advanced treatment options and presence of major market players
are expected to drive market growth in this region.
Key players
Key players operating in the metastatic melanoma therapeutics market are JSC
Belaruskali, Compass Minerals Intl Ltd., Mosaic Company, Uralkali, Rio Tinto
Ltd. Major players are focusing on new product approvals and launches to
strengthen their market position. For instance, in 2021, Bristol Myers Squibb
received FDA approval for Opdualag (nivolumab and relatlimab-rmb) for the
treatment of advanced melanoma.
For more insights, Read- https://www.rapidwebwire.com/metastatic-melanoma-therapeutics-market-trends-size-and-share-analysis/
Get more insights on this topic: https://www.ukwebwire.com/personalized-cell-therapy-market-is-estimated-to-witness-high-growth-owing-to-increasing-prevalence-of-chronic-diseases/
Comments
Post a Comment